Back to results
US 11,267,813 B2Granted
Substituted imidazoquinolines
AssigneeBioNTech SE
InventorChristophe Henry
Life of this patent
Estimating the term…
Abstract
The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.
Claims4
A compound, selected from the group consisting of:
- N-(4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-(tetrahydro-2H-pyran-4-yl)acetamide;
- 1-(4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-(tetrahydro-2H-pyran-4-yl)urea;
- N-(4-(4-amino-2-((ethylamino)methyl)-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-(tetrahydro-2H-pyran-4-yl)acetamide;
- 1-(4-(4-amino-2-((ethylamino)methyl)-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-(tetrahydro-2H-pyran-4-yl)urea;
- N-(4-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-(tetrahydro-2H-pyran-4-yl)acetamide;
- 1-(4-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-(tetrahydro-2H-pyran-4-yl)urea;
- solvates thereof;
- and
- salts thereof.
6 more elements
Dependencies are inferred from the claim text.